HUE029420T2 - Kristályos PI3 kináz inhibitorok - Google Patents

Kristályos PI3 kináz inhibitorok Download PDF

Info

Publication number
HUE029420T2
HUE029420T2 HUE13711105A HUE13711105A HUE029420T2 HU E029420 T2 HUE029420 T2 HU E029420T2 HU E13711105 A HUE13711105 A HU E13711105A HU E13711105 A HUE13711105 A HU E13711105A HU E029420 T2 HUE029420 T2 HU E029420T2
Authority
HU
Hungary
Prior art keywords
compound
formula
lactose
anhydrous form
solid crystalline
Prior art date
Application number
HUE13711105A
Other languages
English (en)
Inventor
Rudy Laurent Maria Broeckx
Walter Ferdinand Maria Filliers
Patrick Hubert J Nieste
Alex Herman Copmans
Filip Marcel C Vanhoutte
Carina Leys
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49160309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE029420(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of HUE029420T2 publication Critical patent/HUE029420T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (5)

  1. : lldltóÖ Sáltól Ippf;|tóp tóik L :|l) Mptórü vegylÄ;
    issTíely 6*(2H(^îv»lîW'3Hl^luli'^^^^0'5//'Pânmüc>(:i^'d|s>lnmky»'l~ii}â«ÎïàU}-'.>H2'kK>rlKWâl)';â' ONO'J^.díbldioksHaxoim-S-iU-^.A^lsjs^-mcloxríÍtlOh.ex-.^-'m^mítí \z.ilárd kristályos vtómépító íor-métàïs. ;2. Az I. ígfiws>oní soritól wgyillst ábol az (Iá kcptóíu .vegyüld szilárd kristály# ibirÄÄn Mm gmeHnïk >0}\>Ό jv> t *1»^'^ s «nah le^vitfbu» 1¾ 2 «tó énak tótól m& I Az ! igénypont szeműi \egvekk ahol az (is keptótó \eg>nfeí szűrne knsmhos formába«. :v«Ps-::»me1ynek rüstigen |tór d»ffirakct#-nm*i»ia csúcsokat sasi dm*« * ' \K~) Π4κ 1M e* ?4 ' ? tótó tók értékeknél.
  2. 4. Az 1-3. Ipiyföstók sz§rÍtóky4|^Ötót gyigyszÉtó4áí tÖÍtói0 aiMkösimrs,
  3. 5, Gyógyszerkészítmény, amely tartóimmá az 1-5. igénypontok bámseh-ske szerimi vegyük- tót egy több -^j|gy^er#ZfIllegaikalmazhaló htgiknzesTel vagy hordozó anyaggal keverve. 6 Az 5. igénypont szentül gyógyszerkészítmény, amely hlgitószafkém vagy hordozó snyvag-któn kktözt tartalmaz.
  4. 7. A ö, igénypont szeried gyégyszetkészúinésiíy, sbeitólaktóz alítótóktóz neonok tórát S> Az 5,, 6, és ?, igénypont#- bármelyike szerinti : gyógyszerkészítmény. amely tartalmaz stóhilizaíos/mt, smcK «rtemtmeo. tómsns c\ szronni ftónatm tonlos kézéi mogvtótsztóe tó &amp;%> igénypont szerinti |yé§yszerfciMtótény, sin! a slaiMälte^ÄÄKä^iBusdjk, IÍy:A f, tpgygom szerinti gyógyszerkészítmény, shot a stóbiiizáíósxer magnézsum-szkarát. II Igénypmnnk báp^lpls- azemd iyéS|é^S:^f^lpénys gp# «A fii képlett - νψ: gyű letet tóiktónMIt ;ÉM^k.^tóilÉsWi,. 119687-14ó°7A SUJG EF2 834 244 Hl k2. A* t-S. igénypontok bármelyike szertnî» vegyfttet-vagy aa S'Π, igénypontok bármelyike scrims gydgysxetfcé&amp;sdtmény as alábbi ssoportMi msgválas®b#á!iap>l;kagaiésében vagy megolôæè-sélm^iSrtèsso aib&amp;lmssPra: ëc|fl -(mm bail Mbikisi fe«o!pa:4s ampysema), asstesg ezê«:^M ma, cisztás iibmsia, s«srkb^ö«íá> IdlofPÉs plMbimm fibrosis., kashexia és tüdő üussorok, islli- IM i*pm mM 1.1. 1'bárás a,· : 'S !«.en\pom*ík. bíomel} sP s^ermu <Γ> K'pieUi u'gUik'î ísí'íOíO kn^sos ur-menées fomifitan tfttén* elbpifplrá, ánpy ttlppazss azt a iépp lop # fe#tetó vegyülhet v/a-ras 1 ·propánéiból kfisiälpsbuak.
  5. 14, A Ok ipnypoa?; $f«rlÜí * »Étpgt&amp;i lépés tartasrn^^8^1* hewep’' séklsU'öi történd khfitésí. fi, %mmm φϋ^ mr^y <«ϋ«Ι» helyik* $Z*rmU spmény agy vagy több dözssp
HUE13711105A 2012-03-13 2013-03-13 Kristályos PI3 kináz inhibitorok HUE029420T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261610012P 2012-03-13 2012-03-13
US201261610023P 2012-03-13 2012-03-13

Publications (1)

Publication Number Publication Date
HUE029420T2 true HUE029420T2 (hu) 2017-02-28

Family

ID=49160309

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13711105A HUE029420T2 (hu) 2012-03-13 2013-03-13 Kristályos PI3 kináz inhibitorok

Country Status (36)

Country Link
US (3) US9642799B2 (hu)
EP (2) EP2834244B1 (hu)
JP (3) JP2015509973A (hu)
KR (2) KR20140141596A (hu)
CN (2) CN104302650B (hu)
AU (2) AU2013234081B2 (hu)
CA (2) CA2864652A1 (hu)
CL (2) CL2014002385A1 (hu)
CO (2) CO7051030A2 (hu)
CR (2) CR20140416A (hu)
CY (1) CY1118565T1 (hu)
DK (1) DK2834244T3 (hu)
EA (2) EA025465B1 (hu)
EC (2) ECSP14018142A (hu)
ES (2) ES2650791T3 (hu)
GT (2) GT201400182A (hu)
HK (2) HK1203487A1 (hu)
HR (1) HRP20161383T1 (hu)
HU (1) HUE029420T2 (hu)
IL (2) IL233886A (hu)
IN (2) IN2014MN01998A (hu)
LT (1) LT2834244T (hu)
MX (2) MX355299B (hu)
MY (1) MY171125A (hu)
NI (2) NI201400100A (hu)
NZ (2) NZ628072A (hu)
PE (2) PE20141964A1 (hu)
PH (2) PH12014501713A1 (hu)
PL (1) PL2834244T3 (hu)
PT (1) PT2834244T (hu)
SG (2) SG11201404519UA (hu)
SI (1) SI2834244T1 (hu)
TW (2) TWI617561B (hu)
UA (1) UA115544C2 (hu)
WO (2) WO2013136076A1 (hu)
ZA (2) ZA201407373B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
SI2834244T1 (sl) 2012-03-13 2016-12-30 Respivert Limited Inhibitorji kristalinične PI3 kinaze
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
JO3279B1 (ar) 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HUE057734T2 (hu) 2013-10-04 2022-06-28 Infinity Pharmaceuticals Inc Heterociklusos vegyületek és alkalmazásuk
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
CR20160600A (es) 2014-07-04 2017-03-07 Lupin Ltd Quinolizione derivados como inhibidores pi3k
ES2701525T3 (es) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As Un procedimiento para la preparación de formulaciones para inhalación
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
SG10202010192YA (en) * 2016-04-15 2020-11-27 Chia Tai Tianqing Pharmaceutical Group Co Ltd Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
WO1999028979A2 (en) 1997-12-02 1999-06-10 Alcatel Usa Sourcing, L.P. Digital phone system
EP1283036B2 (de) 1998-11-13 2020-01-01 Jagotec AG Multidosis-Trockenpulverinhalator mit Pulverreservoir
EP1140938B1 (en) 1999-01-11 2003-08-27 Princeton University High affinity inhibitors for target validation and uses thereof
HUP0200185A3 (en) 1999-03-05 2006-07-28 Chiesi Farma Spa Improved powdery pharmaceutical compositions for inhalation
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2003006628A2 (en) 2001-07-13 2003-01-23 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
WO2003007955A2 (en) 2001-07-20 2003-01-30 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2003301662A1 (en) 2002-10-21 2004-05-13 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
TWI344955B (en) 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
EP1625165A2 (en) 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005004845A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
EP1661879A4 (en) 2003-08-04 2006-11-29 Ono Pharmaceutical Co A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CA2567883A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
CA2569406A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
NZ553696A (en) 2004-09-13 2010-02-26 Ono Pharmaceutical Co Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20080287469A1 (en) 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
CN101448505A (zh) 2006-04-04 2009-06-03 加利福尼亚大学董事会 Pi3激酶拮抗剂
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
CN101495515A (zh) 2006-05-24 2009-07-29 拜耳先灵医药股份有限公司 免疫原性降低的高亲和力人及人源化抗α5β1整联蛋白功能阻断性抗体
AR061664A1 (es) 2006-06-29 2008-09-10 Schering Corp Derivados de himbacina como antagonistas del receptor de trombina biciclicos y triciclicos sustituidos. composiciones farmaceuticas.
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
AU2008250328A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as PI3K lipid kinase inhibitors
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
MX2010007418A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
US8658648B2 (en) 2008-12-05 2014-02-25 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
US20110135655A1 (en) 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CN201676365U (zh) 2010-03-29 2010-12-22 山东京卫制药有限公司 带有语音提示的给药吸入装置
CN201692450U (zh) 2010-06-22 2011-01-05 于清 用于药物输送的高效干粉吸入器
JP5792308B2 (ja) * 2010-08-31 2015-10-07 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 水分制御特性を示す乾燥粉末吸入薬物製品及びその投与方法
BR112013007022B1 (pt) 2010-09-30 2019-10-15 Chiesi Farmaceutici S.P.A Uso de estearato de magnésio
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CN202154919U (zh) 2011-05-03 2012-03-07 王晓明 一种防交叉感染雾化吸入装置
SI2834244T1 (sl) 2012-03-13 2016-12-30 Respivert Limited Inhibitorji kristalinične PI3 kinaze

Also Published As

Publication number Publication date
JP2018008992A (ja) 2018-01-18
PE20142342A1 (es) 2015-01-16
ECSP14018142A (es) 2015-06-30
SI2834244T1 (sl) 2016-12-30
US20150099768A1 (en) 2015-04-09
CA2864652A1 (en) 2013-09-19
EP2825202B1 (en) 2017-09-06
TW201400484A (zh) 2014-01-01
IN2014MN01998A (hu) 2015-08-14
US9642799B2 (en) 2017-05-09
AU2013234080A1 (en) 2014-08-21
CR20140417A (es) 2014-10-31
AU2013234081A1 (en) 2014-08-21
NZ627963A (en) 2015-08-28
PH12014501713A1 (en) 2014-10-13
DK2834244T3 (en) 2016-11-28
PE20141964A1 (es) 2014-12-01
JP6189874B2 (ja) 2017-08-30
IL233886A (en) 2017-12-31
EA201491675A1 (ru) 2014-12-30
TWI586378B (zh) 2017-06-11
MY171125A (en) 2019-09-26
SG11201404519UA (en) 2014-10-30
ECSP14018630A (es) 2015-09-30
JP2015509972A (ja) 2015-04-02
SG11201404522VA (en) 2014-10-30
WO2013136075A1 (en) 2013-09-19
CO7051030A2 (es) 2014-09-10
MX2014010990A (es) 2014-10-13
KR20140141596A (ko) 2014-12-10
PT2834244T (pt) 2016-11-03
AU2013234081B2 (en) 2017-02-02
CR20140416A (es) 2014-10-31
GT201400182A (es) 2015-09-17
PH12014501922A1 (en) 2014-11-24
US20170239256A1 (en) 2017-08-24
KR20140131971A (ko) 2014-11-14
ZA201407374B (en) 2016-10-26
ES2650791T3 (es) 2018-01-22
US20150105408A1 (en) 2015-04-16
CN104284679A (zh) 2015-01-14
CO7061079A2 (es) 2014-09-19
UA115544C2 (uk) 2017-11-27
AU2013234080B2 (en) 2016-12-22
NZ628072A (en) 2015-08-28
CN104302650A (zh) 2015-01-21
HK1203487A1 (zh) 2015-10-30
WO2013136076A1 (en) 2013-09-19
CY1118565T1 (el) 2017-07-12
HK1203812A1 (en) 2015-11-06
HRP20161383T1 (hr) 2016-12-02
TW201350139A (zh) 2013-12-16
PL2834244T3 (pl) 2017-01-31
CL2014002385A1 (es) 2015-01-09
NI201400101A (es) 2016-11-30
MX2014010991A (es) 2014-10-13
CN104302650B (zh) 2017-07-18
CL2014002386A1 (es) 2015-02-27
ZA201407373B (en) 2016-10-26
GT201400183A (es) 2015-07-08
IL233883A0 (en) 2014-09-30
MX357170B (es) 2018-06-27
EP2834244A1 (en) 2015-02-11
NI201400100A (es) 2015-01-12
MX355299B (es) 2018-04-11
TWI617561B (zh) 2018-03-11
CN104284679B (zh) 2017-08-04
EA025465B1 (ru) 2016-12-30
LT2834244T (lt) 2016-11-10
IN2014MN02000A (hu) 2015-08-14
ES2600705T3 (es) 2017-02-10
CA2864643A1 (en) 2013-09-19
EP2825202A1 (en) 2015-01-21
EA201491674A1 (ru) 2014-12-30
EA023715B1 (ru) 2016-07-29
EP2834244B1 (en) 2016-08-10
JP2015509973A (ja) 2015-04-02

Similar Documents

Publication Publication Date Title
AU2013234081B2 (en) Crystalline PI3 kinase inhibitors
JP6353856B2 (ja) ２−（（４−アミノ−３−（３−フルオロ−５−ヒドロキシフェニル）−１ｈ−ピラゾロ［３，４−ｄ］ピリミジン−１−イル）メチル）−３−（２−トリフルオロ−メチル）ベンジル）キナゾリン−４（３ｈ）−オン誘導体及びホスホイノシチド３−キナーゼ阻害剤としてのそれらの使用